Original article

Screening of Egyptian obese children and adolescents for insertion/deletion (I/D) polymorphism in angiotensin-converting enzyme gene

Zeinab A. El-Kabbany a, Rasha T. Hamza a, Dina M. Shinkar a,*, Tarek M. Kamal b, Reham I. Abdelmageed a,b, Mina S. Said c, Mennatullah I. Abdel-Hamid c

a Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Human Medical Genetics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
c Egyptian Ministry of Health, Cairo, Egypt

ABSTRACT

Background: Aims: The role of angiotensin-converting enzyme (ACE) gene polymorphism in the development of obesity and hypertension in children has not been widely studied. We aimed to screen Egyptian obese children and adolescents for insertion/deletion (I/D) polymorphism in the ACE gene.

Methods: One hundred forty-two children and adolescents were included (70 with simple obesity and 72 controls). Blood pressure was measured, and anthropometric parameters were assessed in all included children and adolescents. Fasting lipid profile, fasting glucose, and insulin were measured. DNA extraction and ACE I/D polymorphism genotyping were also performed.

Results: Obese children had a higher frequency of DD genotype (30% in obese versus 11.1% in controls, \( P < .001 \)) and D alleles (61.8% in obese versus 48.6% in controls, \( P = .01 \)) compared with controls. Obese children with hypertension and prehypertension had higher frequency of DD genotype than II genotype and higher D alleles than I alleles. DD genotype and D allele were independently associated with hypertension (OR: 9.86 and 11.57, respectively, \( P < .001 \)), while dyslipidemia and insulin resistance were not associated with the ACE I/D gene polymorphism.

Conclusion: DD genotype and D-allele of the ACE gene polymorphism were associated with obesity and hypertension in Egyptian children.

© 2019 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Pediatric obesity has turned into a critical public health problem, as its pervasiveness inside the pediatric population has been extraordinarily expanded in the most recent decades. [1] Morbidities related to obesity, such as hypertension, diabetes mellitus, and hyperlipidemia, were viewed as diseases of adults. Nonetheless, presently, they have progressed toward becoming diseases of children. [2] Obesity is hereditary occurring in approximately 40% of cases, and this happens through numerous genes [3]. Renin-angiotensin system (RAS) mediates controlling blood pressure and the body fluid status [4]. It also controls blood volume and vascular function. The polymorphism in the angiotensin-converting enzyme (ACE) gene takes the form of insertion (I) or deletion (D) of a part in intron 16 that is located at 17q23. Presence of D allele is responsible for the creation of large amounts of ACE. [5,6]

Renin is produced from the juxtaglomerular apparatus of the kidney. It converts angiotensinogen to angiotensin I (Ang-I), and then, it is converted to Ang-II by the ACE [7]. The presence of DD genotype results in 65% higher action of ACE than II genotypes, which, in turn, makes obese children 3.5 times more susceptible to

https://doi.org/10.1016/j.ijpam.2019.02.008

2352-6467/© 2019 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
hypertension than normal-weight children [8].

Studies examining the relationship of genes, particularly angiotensin-converting enzyme insertion/deletion (ACE I/D) on obesity and hypertension in children, are few. The aim of the present study was to screen Egyptian obese children and adolescents for insertion/deletion (I/D) polymorphism in the ACE gene and to assess its relation to hypertension, insulin resistance, and dyslipidemia.

2. Subjects and methods

2.1. Study population

This study was conducted at Ain-Shams University Children Hospital. The local ethical board has approved the study protocol. Informed consent was obtained from guardians of included children and from children over 12 years of age according to the Declaration of Helsinki.

One hundred forty-two children and adolescents aged between 3 and 16 years participated in the study. Among them, 70 had simple obesity and 72 were healthy matched normal controls. Children and adolescents with obesity came for follow-up in the obesity clinic, while controls were healthy children and adolescents who came to the pediatric outpatient clinic with their siblings who had simple illnesses. Cases were diagnosed as having obesity when their body mass index (BMI) was above the 95th percentile or BMI had simple illnesses. Cases were diagnosed as having obesity when their body mass index (BMI) was above the 95th percentile or BMI had simple illnesses. Cases were diagnosed as having obesity when their body mass index (BMI) was above the 95th percentile or BMI had simple illnesses. Cases were diagnosed as having obesity when their body mass index (BMI) was above the 95th percentile or BMI.

Exclusion criteria: Children and adolescents were excluded from the study if they had genetic abnormalities or endocrinal diseases or were receiving drugs that could alter weight, such as antidepressants, antiepileptics or if they were taking lipid-lowering drugs.

History was taken from all included children about comorbidities such as diabetes mellitus, hypertension, and heart diseases. Additionally, a thorough clinical examination was performed.

2.2. Measurement of anthropometric parameters and blood pressure

All included children were subjected to accurate weight, height, waist circumference, and hip circumference measurement. Body mass index (BMI) was calculated, and BMI SDS was plotted. [9] Further, the waist-to-hip ratio was calculated [10]. Blood pressure was measured accurately at several occasions, and the average was plotted on percentiles [11]. Prehypertension was defined as systolic or diastolic blood pressure ≥90th percentile but less than 95th percentile, and hypertension was defined as systolic blood pressure or diastolic blood pressure ≥95th percentile.

2.3. Measurement of lipid profile and fasting insulin

Fasting cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and fasting blood glucose were measured. Diabetes mellitus was defined as fasting blood glucose more than or equal to 126 mg/dl [12].

Fasting insulin was analysed, and HOMA-IR (homeostasis model assessment for insulin resistance index) was calculated. Insulin resistance was defined as HOMA-IR ≥ 3.16.

2.4. Genetic analysis

DNA was extracted from lymphocytes by the spin column method of GeneJET™ Genomic DNA purification kit (#K072, Pure-Extreme @ Fermentas Life Sciences, Thermo Fisher Scientific, Vilnius, Lithuania).

Oligonucleotides were synthesized specifically for amplification of a DNA fragment that was 490 bp and located in intron 16 by polymerase chain reaction to determine the ACE I/D genotype (rs4340) [13,14]. The primers used were Forward: 5’CTGGAGACCTCCATCCTTTTCT-3’, and reverse: 5’GATGTGGCATCATTCGTGAGAT-3’.

PCR analysis (Biometra™) consisted of DNA denaturation at 95 °C followed by 30 cycles of PCR. The produced genotypes were a 190 bp band (D/D); a 490 bp DNA band (I/I); or two bands of 190 bp and 490 bp (I/D). They were separated by electrophoresis on a 2% agarose gel, which was used for separation of bands by electrophoresis in Tris EDTA (ethylenediamine tetraacetic acid)-Borate buffer (TBE). The products were stained and examined under ultraviolet light. This was documented using DNA analysis software (InGenius Syngene™ – UK).

Genotype distribution was tested by Hardy-Weinberg equilibrium (HWE) in obese and controls.

2.5. Statistical analysis

The chi-square test was used to compare categorical data between two groups for categorized data, while the Student t-test was used to compare quantitative data between two groups. The odds ratio (OR) and 95% confidence intervals (95% (CI)) were used to determine liability to disease. The independent effect of different variables on hypertension was determined by logistic regression analysis. A P value < .05 was considered to be statistically significant. The statistical analysis was conducted using SPSS version 22.0.

3. Results

The mean age of obese children was 8.9 years, and 57.1% were males. Children in the control group were comparable regarding age and sex (P > .05; Table 1). Data of fasting blood glucose, insulin, and fasting lipid profile of all included children are shown in Table 1.

Among the group with obesity, the median BMI SDS was 32.08 (7.05), waist circumference was 48.88, hip circumference SDS was 3.29, and waist-to-hip ratio was 2.23. Of the 70 obese children, 10 (14.3%) were hypertensives and 18 (25.7%) were prehypertensives, while none of the 70 normal children had hypertension, and 5 (6.9%) had prehypertension.

The genotype frequencies among children and adolescents with obesity and controls are presented in Table 2. Of obese children, 30% were DD genotype compared to only 11.1% of controls. Children with DD genotype had a 3.4-fold more risk of obesity (odds ratio [OR] 3.45, 95% confidence interval [CI], 1.26 to 9.48, P = .005). In addition, 51.4% of those with obesity were having at least one D allele compared to 38.2% of controls (OR, 1.71, 95% CI, 1.07 to 2.75; P = .024).

Children with DD genotype had a higher weight for height SDS than those with II genotype (P = .001) and ID genotype (P = .002), with no significant difference between ID and II genotypes (P = .807). Further, children with DD genotype had higher BMI SDS, waist circumference SDS, and hip circumference SDS than those with II genotype (P = .003, .007, and 0.017, respectively). Children with DD genotype had significantly higher BMI SDS than those with ID genotype (P = .003), with no significant difference between ID and II genotypes (P = .408) as shown in Table 3.

Obese children with hypertension had a significantly higher frequency of DD genotype than those with normal blood pressure as shown in Fig. 1. Logistic regression analysis showed that the DD genotype was independently associated with hypertension (OR, 9.86, 95% CI, 2.98 to 32.65; P < .001).

Fasting cholesterol, fasting triglycerides, and fasting LDL did not
show significant difference between DD genotype and II genotype and did not show significant difference between DD genotype and ID genotype. Furthermore, fasting blood glucose, insulin, and HOMA-IR did not show significant difference between DD genotype and II genotype and did not show significant difference between DD genotype and ID genotype as shown in Table 3.

4. Discussion

Many studies in adults have suggested the genetic contribution to obesity. This is the first study to analyze the association of ACE I/D polymorphism with obesity and hypertension in Egyptian children and adolescents.

Thus far, the role of ACE in obesity is not clarified. It is suggested that RAS affects the adipose tissue and the satiety centers [15]. A decrease in renin-angiotensin system activity usually results in weight loss. Further, weight gain could be prevented by providing angiotensin-converting enzyme inhibitors, according to the results of an animal study [16,17]. Fat deposition was reported to be mediated by angiotensin II [18]. Moreover, type II diabetes can be prevented by providing angiotensin-converting enzyme inhibitors [19]. Furthermore, adipose tissue can produce angiotensinogen [20]. RAS can have a major role in control of blood pressure, obesity, and metabolic syndrome through the regulation of vascular tone

---

Table 1
Clinical and laboratory characteristics of obese children and adolescents with obesity and controls.

| Characteristics                  | Obese children n = 70 | Controls n = 72 | P value |
|----------------------------------|------------------------|----------------|---------|
| Age (years)                      | 8.91 (3.71)            | 7.97 (3.15)    | .103a   |
| Sex (male), n (%)                | 40 (57.1)              | 45 (62.5)      | .515b   |
| Positive family history, n (%)   | 31 (44.3)              | 14 (19.4)      | <.001b  |
| Fasting blood glucose (mmol/L)   | 5.41 (1.3)             | 4.12 (0.39)    | <.001a  |
| Fasting insulin (µU/ml)          | 3.88 (3.31)            | 3.88 (3.31)    | .001a   |
| HOMA–IR                          | 3.01 (0.92)            | 3.01 (0.92)    | .001a   |
| Total cholesterol (mmol/L)       | 4.27 (1.56)            | 3.66 (1.22)    | .011a   |
| Fasting triglycerides (mmol/L)   | 1.54 (0.95)            | 1.08 (0.48)    | <.001a  |
| Fasting HDL (mmol/L)             | 1.15 (0.56)            | 1.37 (0.66)    | <.001a  |
| Fasting LDL (mmol/L)             | 2.14 (1.28)            | 2.18 (1.21)    | .861a   |

BMI: Body mass index, SDS: Standard deviation score, HOMA-IR: Homeostasis model assessment for insulin resistance. HDL: High-density lipoprotein, LDL: low-density lipoproteins.

Values in parentheses are percentages, or data are presented as mean and standard deviation. a: Independent t-test; b: Chi-square test.

Table 2
Distribution of the ACE I/D genotypes and alleles in children and adolescents with obesity and controls.

| Genotype | Obese children | Controls | OR (95% CI) | P value |
|----------|----------------|----------|-------------|---------|
| Genotype, n (%) | n | % | n | % | Reference |
| II       | 19 | 27.1 | 25 | 34.7 | Referent |
| ID       | 30 | 42.9 | 39 | 54.2 | 1.012 (0.472–2.17) | .177 |
| DD       | 21 | 30.0 | 8 | 11.1 | 3.45 (1.26–9.48) | .005 |

Allele, n (%)

| Allele | n | % | n | % | Referent |
|--------|---|---|---|---|----------|
| I      | 68 | 48.6 | 89 | 61.8 | 1.71 (1.07–2.75) | .024 |
| D      | 72 | 51.4 | 55 | 38.2 | Referent |

OR odds ratio, 95% CI confidence interval. P value < .05 indicates a significant difference.

---

Table 3
ACE I/D genotype in relation to anthropometric measures, lipid profile, and glucose homeostasis parameters in children and adolescents with obesity.

|                      | II | n = 19 | ID | n = 30 | DD | n = 21 | P value | P value |
|----------------------|----|--------|----|--------|----|--------|---------|---------|
| Weight for height SDS (IQR) | 2.5 (2.38–3.3) | 2.51 (1.85–3) | 3.64 (2.7–4.44) | .807a | .001 | .002 |
| BMI SDS, median (IQR)    | 3.06 (2.65–3.7) | 3.26 (2.91–3.72) | 3.89 (3.3–5.1) | .408a | .003 | .001 |
| Waist circumference SDS, median (IQR) | 3.91 (3.12–5.08) | 4.85 (3.38–5.3) | 5.14 (4.08–7.06) | .171a | .110 | .007 |
| Hip circumference SDS, median (IQR) | 2.5 (2.29–3.43) | 3.67 (2.94–4.6) | 4.27 (2.92–4.91) | .019a | .427 | .017 |
| Waist/hip ratio SDS, median (IQR) | 1.48 (0.6–2.5) | 2.1 (1.2–4.25) | 2.67 (2–3.75) | .238a | .515 | .056 |
| Total fasting cholesterol (mmol/L), mean ± SD | 4.11 (0.93) | 4.62 (1.95) | 3.91 (1.31) | .262b | .703 | .689 |
| Fasting triglycerides (mmol/L), mean ± SD | 1.60 (1.16) | 1.65 (0.83) | 1.67 (0.95) | .857b | .952 | .824 |
| Fasting HDL (mmol/L), mean ± SD | 1.27 (0.42) | 1.51 (0.85) | 1.24 (0.52) | .227b | .200 | .974 |
| LDL (mmol/L), mean ± SD | 2.12 (1.07) | 2.37 (1.41) | 1.83 (1.27) | .496b | .142 | .485 |
| Fasting blood glucose (mmol/L), mean ± SD | 5.24 (0.97) | 5.71 (1.67) | 5.14 (0.82) | .220b | .124 | .801 |
| Fasting insulin (µU/mL), mean ± SD | 6.04 (2.18) | 6.46 (2.76) | 5.70 (2.63) | .577b | .328 | .660 |
| HOMA-IR, mean ± SD | 3.9 (0.74) | 3.6 (0.89) | 4.0 (0.89) | .226b | .120 | .703 |

BMI: Body mass index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HOMA-IR: Homeostasis model assessment for insulin resistance. a: Kruskal–Wallis; b: One-Way ANOVA. Post-hoc analysis was done to compare the genotype subgroups. P value < .05 indicates a significant difference.
and fluid status [21]. ACE gene inhibition leads to a decrease in blood pressure [22].

In the present study, 25.7% of obese children had pre-hypertension and 14.3% had hypertension. This finding was similar to findings from previous studies that concluded that obesity is positively correlated with hypertension [23]. Previous adult studies reported that D allele carriers have a higher BMI than II genotype carriers. They were also more liable to hypertension [24,25]. ACE D alleles were found to have an effect on blood pressure in a study with adolescents. A relation between blood pressure and the ACE I/D polymorphism in the ACE gene was significantly higher in obese children and adolescents and in those with hypertension. Lipid profile and glucose homeostasis were not associated with the I/D polymorphism genotypes. Further larger studies should be performed with measurement of ACE level and the ACE gene polymorphism to confirm these results and to search for methods of prevention of obesity and hypertension in children by understanding its genetic etiology.

Funding

No funding was received for this research.

Conflict of interest

No conflict of interest to declare.

Acknowledgment

We thank the staff of Pediatric Obesity Clinic in Ain-Shams University hospitals for their collaboration in sampling as well as the children who participated in the study.

References

[1] Turudic S. Prevalence of overweight and obesity among 5-6-year-old children in North Part of Serbia. Arch Dis Child 2014;99:274–5.
[2] Conroy R, Espinal Y, Fennoy I, Accacha S, Boucher-Berry C, Carey DE. Retinol binding protein 4 is associated with adiposity-related co-morbidity risk factors in children. J Pediatr Endocr Met 2011;24:913–9.
[3] Rankinen T, Zuberi A, Chagguon YC, Weinagel SJ, Argyropoulos G, Walts B, Perusse L, Bouchard C. The human obesity gene map: the 2005 update. Obesity 2006;14:529–644.
[4] Fyhrquist F, Sajonmaa O. Renin-angiotensin system re. J Intern Med 2008;264:224–36.
[5] Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–6.
[6] Tietz L, Rigat B, Vuvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197–205.
[7] Norton GR, Brookbank R, Woodwiss AJ. Gene variants of the renin–angiotensin systemand hypertension: from trough of disillusionment to a welcome phase of enlightenment? Clin Sci (Lond) 2010;118:487–506.
[8] Eisenmann JC, Wrede J, Heelan KA. Associations between adiposity, family history of CHD and blood pressure in 3–8 year old children. J Hum Hypertens 2005;19:675–81.
[9] Cole TJ. A chart to link childcentiles of body mass index, weight and height. Eur J Clin Nutr 2002;56:1194–9.
[10] Schwandt P, Kelishadi R, Haas GM. First reference curves of waist circumference for German children in comparison to international values: the PEP Family Heart Study. World J Pediatr 2008;4:259–66.
[11] National High Blood Pressure Education Program (NHBPEP). The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555–76.
[12] American Diabetes Association Standards of Care for Diabetes. Brief summary of screening and diagnosis of type 2 diabetes and its complications. Diabetes Care 2013;36:S11–66.
[13] Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DEP1) (dipeptidyldipeptidase 1). Nucleic Acids Res 1992;20:1433.
[14] Solini A, Giacchetti G, Sfriso A, Fioretto P, Sardi C, Saller A, Tonolo G, Maisi M, Mantero F, Nosadini R. Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. Am J Kidney Dis 1999;34:1002–9.
[15] Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010;100:525–34.
[16] Engeli S, Böhne J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356–62.
[17] Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2002;10:431–6.
[18] Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002;40:609–11.
[19] Scheen AJ. Value: analysis of results. Lancet 2004;364:932–3.
[20] Paul M, Poyan Mehr A, Krenz R. Physiolo gy of local renin–angiotensin sys- tems. Physiol Rev 2006;86:747–803.
[21] Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocri- nology 1999;140:154–8.
[22] Kregel JH, John SW, Langembach, et al. L. Male II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 2004;145:101–8.
[23] Procopciuc LM, Sitar-Taut A, Pop D, Sitar-Taut DA, Olteanu I, Zdrenghea D. Renin-angiotensin system polymorphisms in patients with metabolic syn- drome (MetS). Eur J Intern Med 2010;21:414–8.
[24] Porto PI, Garcia SI, Dieuzeide G, Gonzalez C, Pirola CJ. Renin-angiotensin-aldosterone system loci and multilocus interactions in young-onset essential hypertension. Clin Exp Hypertens 2003;25:117–30.
[25] Strazzullo P, Iacono R, Iacovelllo L, Russo O, Barba G, Russo P, D’Orazio A, Barbato A, Cappuccio FP, Farinara E, Siani A. Olivetti prospective heart study. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti prospective heart study. Ann Intern Med 2003;138:17–23.
[26] Lemes VA, Neves AL, Guazzelli IC, Frazzatto E, Nicolau C, Corrêa-Giannella ML, Velho G, Villares SM. Angiotensin converting enzyme insertion/deletion polymorphism is associated with increased adiposity and blood pressure in obese children and adolescents. Genes 2013;52:197–202.
[27] Zarouk WA, Hussein IR, Esmail NN, Raslan HM, Rehein HAA, Moguib O, Emara NA, Aly AA, Hamed M. Association of angiotensin converting enzyme gene (I/D) polymorphism with hypertension and type 2 diabetes. Bratisl Lek Listy 2012;113:14–8.